Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials

Preetha Balasubramanian, Constance Williams, Mariya B. Shapiro, Faruk Sinangil, Keith Higgins, Arthur Nádas, Maxim Totrov, Xiang Peng Kong, Andrew J. Fiore-Gartland, Nancy Haigwood, Susan Zolla-Pazner, Catarina E. Hioe

    Research output: Contribution to journalArticle

    5 Citations (Scopus)

    Abstract

    Immunization with HIV AIDSVAX gp120 vaccines in the phase III VAX003 and VAX004 trials did not confer protection. To understand the shortcomings in antibody (Ab) responses induced by these vaccines, we evaluated the kinetics of Ab responses to the V1V2 and V3 regions of gp120 and the induction of Ab-mediated antiviral functions during the course of 7 vaccinations over a 30.5-month period. Plasma samples from VAX003 and VAX004 vaccinees and placebo recipients were measured for ELISA-binding Abs and for virus neutralization, Ab-dependent cellular phagocytosis (ADCP), and Ab-dependent cellular cytotoxicity (ADCC). Ab responses to V1V2 and V3 peaked after 3 to 4 immunizations and declined after 5 to 7 immunizations. The deteriorating responses were most evident against epitopes in the underside of the V1V2 β-barrel and in the V3 crown. Correspondingly, vaccinees demonstrated higher neutralization against SF162 pseudovirus sensitive to anti-V1V2 and anti-V3 Abs after 3 or 4 immunizations than after 7 immunizations. Higher levels of ADCP and ADCC were also observed at early or mid-time points as compared with the final time point. Hence, VAX003 and VAX004 vaccinees generated V1V2- and V3-binding Abs and functional Abs after 3 to 4 immunizations, but subsequent boosts did not maintain these responses.

    Original languageEnglish (US)
    Article number18863
    JournalScientific Reports
    Volume8
    Issue number1
    DOIs
    StatePublished - Dec 1 2018

    Fingerprint

    HIV Envelope Protein gp120
    Antibody Formation
    Immunization
    Vaccines
    Phagocytosis
    Antibodies
    Virus Attachment
    Crowns
    Antiviral Agents
    Epitopes
    Vaccination
    Enzyme-Linked Immunosorbent Assay
    Placebos

    ASJC Scopus subject areas

    • General

    Cite this

    Balasubramanian, P., Williams, C., Shapiro, M. B., Sinangil, F., Higgins, K., Nádas, A., ... Hioe, C. E. (2018). Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials. Scientific Reports, 8(1), [18863]. https://doi.org/10.1038/s41598-017-18863-0

    Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials. / Balasubramanian, Preetha; Williams, Constance; Shapiro, Mariya B.; Sinangil, Faruk; Higgins, Keith; Nádas, Arthur; Totrov, Maxim; Kong, Xiang Peng; Fiore-Gartland, Andrew J.; Haigwood, Nancy; Zolla-Pazner, Susan; Hioe, Catarina E.

    In: Scientific Reports, Vol. 8, No. 1, 18863, 01.12.2018.

    Research output: Contribution to journalArticle

    Balasubramanian, P, Williams, C, Shapiro, MB, Sinangil, F, Higgins, K, Nádas, A, Totrov, M, Kong, XP, Fiore-Gartland, AJ, Haigwood, N, Zolla-Pazner, S & Hioe, CE 2018, 'Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials', Scientific Reports, vol. 8, no. 1, 18863. https://doi.org/10.1038/s41598-017-18863-0
    Balasubramanian P, Williams C, Shapiro MB, Sinangil F, Higgins K, Nádas A et al. Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials. Scientific Reports. 2018 Dec 1;8(1). 18863. https://doi.org/10.1038/s41598-017-18863-0
    Balasubramanian, Preetha ; Williams, Constance ; Shapiro, Mariya B. ; Sinangil, Faruk ; Higgins, Keith ; Nádas, Arthur ; Totrov, Maxim ; Kong, Xiang Peng ; Fiore-Gartland, Andrew J. ; Haigwood, Nancy ; Zolla-Pazner, Susan ; Hioe, Catarina E. / Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
    @article{92b4c4423b264966bc4e157f48b5ede5,
    title = "Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials",
    abstract = "Immunization with HIV AIDSVAX gp120 vaccines in the phase III VAX003 and VAX004 trials did not confer protection. To understand the shortcomings in antibody (Ab) responses induced by these vaccines, we evaluated the kinetics of Ab responses to the V1V2 and V3 regions of gp120 and the induction of Ab-mediated antiviral functions during the course of 7 vaccinations over a 30.5-month period. Plasma samples from VAX003 and VAX004 vaccinees and placebo recipients were measured for ELISA-binding Abs and for virus neutralization, Ab-dependent cellular phagocytosis (ADCP), and Ab-dependent cellular cytotoxicity (ADCC). Ab responses to V1V2 and V3 peaked after 3 to 4 immunizations and declined after 5 to 7 immunizations. The deteriorating responses were most evident against epitopes in the underside of the V1V2 β-barrel and in the V3 crown. Correspondingly, vaccinees demonstrated higher neutralization against SF162 pseudovirus sensitive to anti-V1V2 and anti-V3 Abs after 3 or 4 immunizations than after 7 immunizations. Higher levels of ADCP and ADCC were also observed at early or mid-time points as compared with the final time point. Hence, VAX003 and VAX004 vaccinees generated V1V2- and V3-binding Abs and functional Abs after 3 to 4 immunizations, but subsequent boosts did not maintain these responses.",
    author = "Preetha Balasubramanian and Constance Williams and Shapiro, {Mariya B.} and Faruk Sinangil and Keith Higgins and Arthur N{\'a}das and Maxim Totrov and Kong, {Xiang Peng} and Fiore-Gartland, {Andrew J.} and Nancy Haigwood and Susan Zolla-Pazner and Hioe, {Catarina E.}",
    year = "2018",
    month = "12",
    day = "1",
    doi = "10.1038/s41598-017-18863-0",
    language = "English (US)",
    volume = "8",
    journal = "Scientific Reports",
    issn = "2045-2322",
    publisher = "Nature Publishing Group",
    number = "1",

    }

    TY - JOUR

    T1 - Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials

    AU - Balasubramanian, Preetha

    AU - Williams, Constance

    AU - Shapiro, Mariya B.

    AU - Sinangil, Faruk

    AU - Higgins, Keith

    AU - Nádas, Arthur

    AU - Totrov, Maxim

    AU - Kong, Xiang Peng

    AU - Fiore-Gartland, Andrew J.

    AU - Haigwood, Nancy

    AU - Zolla-Pazner, Susan

    AU - Hioe, Catarina E.

    PY - 2018/12/1

    Y1 - 2018/12/1

    N2 - Immunization with HIV AIDSVAX gp120 vaccines in the phase III VAX003 and VAX004 trials did not confer protection. To understand the shortcomings in antibody (Ab) responses induced by these vaccines, we evaluated the kinetics of Ab responses to the V1V2 and V3 regions of gp120 and the induction of Ab-mediated antiviral functions during the course of 7 vaccinations over a 30.5-month period. Plasma samples from VAX003 and VAX004 vaccinees and placebo recipients were measured for ELISA-binding Abs and for virus neutralization, Ab-dependent cellular phagocytosis (ADCP), and Ab-dependent cellular cytotoxicity (ADCC). Ab responses to V1V2 and V3 peaked after 3 to 4 immunizations and declined after 5 to 7 immunizations. The deteriorating responses were most evident against epitopes in the underside of the V1V2 β-barrel and in the V3 crown. Correspondingly, vaccinees demonstrated higher neutralization against SF162 pseudovirus sensitive to anti-V1V2 and anti-V3 Abs after 3 or 4 immunizations than after 7 immunizations. Higher levels of ADCP and ADCC were also observed at early or mid-time points as compared with the final time point. Hence, VAX003 and VAX004 vaccinees generated V1V2- and V3-binding Abs and functional Abs after 3 to 4 immunizations, but subsequent boosts did not maintain these responses.

    AB - Immunization with HIV AIDSVAX gp120 vaccines in the phase III VAX003 and VAX004 trials did not confer protection. To understand the shortcomings in antibody (Ab) responses induced by these vaccines, we evaluated the kinetics of Ab responses to the V1V2 and V3 regions of gp120 and the induction of Ab-mediated antiviral functions during the course of 7 vaccinations over a 30.5-month period. Plasma samples from VAX003 and VAX004 vaccinees and placebo recipients were measured for ELISA-binding Abs and for virus neutralization, Ab-dependent cellular phagocytosis (ADCP), and Ab-dependent cellular cytotoxicity (ADCC). Ab responses to V1V2 and V3 peaked after 3 to 4 immunizations and declined after 5 to 7 immunizations. The deteriorating responses were most evident against epitopes in the underside of the V1V2 β-barrel and in the V3 crown. Correspondingly, vaccinees demonstrated higher neutralization against SF162 pseudovirus sensitive to anti-V1V2 and anti-V3 Abs after 3 or 4 immunizations than after 7 immunizations. Higher levels of ADCP and ADCC were also observed at early or mid-time points as compared with the final time point. Hence, VAX003 and VAX004 vaccinees generated V1V2- and V3-binding Abs and functional Abs after 3 to 4 immunizations, but subsequent boosts did not maintain these responses.

    UR - http://www.scopus.com/inward/record.url?scp=85040445454&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85040445454&partnerID=8YFLogxK

    U2 - 10.1038/s41598-017-18863-0

    DO - 10.1038/s41598-017-18863-0

    M3 - Article

    C2 - 29323175

    AN - SCOPUS:85040445454

    VL - 8

    JO - Scientific Reports

    JF - Scientific Reports

    SN - 2045-2322

    IS - 1

    M1 - 18863

    ER -